[Acute coronary syndrome risk management].
Coronary atherosclerosis begins in early life and progresses through adulthood, exacerbated by various risk factors. The past decade has witnessed an increasing recognition that endothelial dysfunction and inflammatory mechanisms play a central role in the pathogenesis of atherosclerosis and acute coronary syndrome (ACS). Advances in the management of patients with ACS have evolved dramatically. Recently the concept of interventional cardiology expand beyond mechanical revascularization to embrace preventive interventions that forestall future cardiac and vascular events. The pleiotropic effect of preventive agents contributes to early and significant risk reduction in high-risk patients and also after being suffered from ACS.
Shimamoto
Ken
K
Department of Cardiology, Tokyo Women's Medical University Aoyama Hospital.
Kawana
Masatoshi
M
D000789:Angina, Unstable / Q000209:etiology / Q000517:prevention & control*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage; D003324:Coronary Artery Disease / Q000150:complications; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D006937:Hypercholesterolemia / Q000150:complications / Q000628:therapy; D006973:Hypertension / Q000150:complications / Q000628:therapy; D008019:Life Style; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control*; D018384:Oxidative Stress; D011322:Primary Prevention; D012307:Risk Factors; D013577:Syndrome; D045162:Thiazolidinediones / Q000008:administration & dosage
D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D045162:Thiazolidinediones; D001241:Aspirin